Nick Leschly

Nick Leschly is a biotechnology executive and entrepreneur with over two decades of leadership experience advancing transformative therapies for patients. He currently serves as Baker Brothers Advisor and Entrepreneur and Executive Chair of a stealth glioblastoma-focused biotech company. Mr. Leschly brings deep expertise in building and scaling biotechnology companies, corporate strategy, and novel drug development in the cell and gene therapy industry.

Mr. Leschly was most recently CEO and Chair of 2seventy bio, guiding the company’s successful spin-out from bluebird bio and establishing it as an oncology-focused cell therapy company, later sold to Bristol Myers Squibb. Previously, he was CEO of bluebird bio where he led the company for 12+ years, scaling it from an early-stage gene therapy startup to a publicly traded leader in cell and gene therapies.

Earlier in his career, Mr. Leschly was a founding partner at Third Rock Ventures, where he played a key role in launching and building innovative biotech startups including Agios Pharmaceuticals.

Mr. Lescly holds a B.S. in molecular biology from Princeton University and an M.B.A. from The Wharton School of the University of Pennsylvania. He is a board member of Rethink Foods in NYC and The CEPIA School in Costa Rica.